SEC Filings
AbbVie Assigns $9.1 Billion Of Its $10.6 Billion Apogee Price To Unapproved Drugs
AbbVie's accounting for the Apogee deal is preliminary, with $2.284 billion of goodwill and a $1.661 billion deferred tax liability.
ABBV
AbbVie (ABBV) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
AbbVie Director Jennifer Davis Leaves Board After Being Named CEO Of Align Technology
The Class II director told AbbVie's board on Wednesday she would resign effective Monday, saying no dispute with the company was involved.
Earnings
AbbVie CEO Says Analysts Are Underrating Etentamig, A Multibillion-Dollar Myeloma Drug
Rob Michael named four pipeline assets he says Wall Street undervalues, while saying future deals will be smaller than Allergan.
SEC Filings
AbbVie Raises 2026 Profit Forecast After Skyrizi And Rinvoq Lift Sales 10.3% To $17.4 Billion
The drugmaker also lifted its quarterly dividend 5.2% to $1.82 and completed its Apogee Therapeutics purchase as Humira sales fell.
SEC Filings
AbbVie Adds A Thirteenth Board Seat For UC San Diego Health Sciences Vice Chancellor John Carethers
The board grew from twelve to thirteen directors, and the new member was placed on its Public Policy and Sustainability Committee.
Earnings
AbbVie Cuts Full-Year Profit Guidance To $13.76-$13.96 A Share After $216 Million Research Charge
An 8-K puts a $0.11-per-share hit in the third quarter and lowers both the quarterly and full-year adjusted earnings ranges.